
Insmed (INSM) Stock Forecast & Price Target
Insmed (INSM) Analyst Ratings
Bulls say
Insmed is poised for long-term success as their two commercial products show strong potential and their robust clinical pipeline targets key therapeutic areas with significant unmet needs. The company's recent impressive financial results and guidance from the Brinsupri launch, combined with their promising peak revenue estimates for both Brinsupri and TPIP, position them for continued growth and potential upside. However, risks such as potential competition, clinical and regulatory obstacles, and commercialization challenges should be monitored closely.
Bears say
Insmed is a biopharmaceutical company with a diverse portfolio of respiratory and inflammatory assets. Despite its strong commercial and clinical programs, the company has a history of significant financial losses and a high level of debt. Additionally, its commercial products Arikayce and Brinsupri have limited peak sales potential, and its pipeline program for TPIP faces potential challenges with a small sample size and lack of measured primary endpoints.
This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.
Insmed (INSM) Analyst Forecast & Price Prediction
Start investing in Insmed (INSM)
Order type
Buy in
Order amount
Est. shares
0 shares